Alerts will be sent to your verified email
Verify EmailASPIRA
|
Aspira Pathlab&Diagn
|
Nephro Care India
|
Invicta Diagnostic
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
5.54 % | 144.26 % | 36.05 % |
|
5yr average Equity Multiplier
|
1.42 | 18.06 | 1.54 |
|
5yr Average Asset Turnover Ratio
|
1.0 | 1.28 | 1.21 |
|
5yr Avg Net Profit Margin
|
-3.89 % | 8.51 % | 20.01 % |
|
Price to Book
|
11.9 | 1.95 | 0.0 |
|
P/E
|
2551.48 | 33.06 | 15.46 |
|
5yr Avg Cash Conversion Cycle
|
-26.26 Days | -60.13 Days | 3155.19 Days |
|
Inventory Days
|
10.15 Days | 6.87 Days | 7.26 Days |
|
Days Receivable
|
38.11 Days | 13.4 Days | 14.01 Days |
|
Days Payable
|
81.06 Days | 75.6 Days | -2240.05 Days |
|
5yr Average Interest Coverage Ratio
|
0.45 | 32.99 | 40.66 |
|
5yr Avg ROCE
|
-0.04 % | 25.8 % | 37.62 % |
|
5yr Avg Operating Profit Margin
|
6.02 % | 13.74 % | 37.67 % |
|
5 yr average Debt to Equity
|
0.1 | 10.46 | 0.32 |
|
5yr CAGR Net Profit
|
n/a | 109.59 % | 82.73 % |
|
5yr Average Return on Assets
|
-2.37 % | 12.63 % | 23.37 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
18.39 % | 61.71 % | 66.7 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-1.08 % | 0.33 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Aspira Pathlab&Diagn
|
Nephro Care India
|
Invicta Diagnostic
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|